Paysign Reports 23% Growth in Revenues

image

Paysign Reports 23% Growth in Revenues

Paysign, Inc. (PAYS) reported a significant year-over-year revenue increase in its third-quarter earnings call, indicating strong performance particularly in the patient affordability business. CEO Mark Newcomer announced revenues reached $15.3 million, marking a 23% increase, and adjusted EBITDA rose 20.6% to $2.8 million. The company also unveiled plans to expand its program offerings, including a new partnership with a leading pharmaceutical company. Despite challenges in the plasma business and ongoing investments, Paysign has a positive outlook for the remainder of the year, forecasting revenues between $56.5 million and $58.5 million, and net income between $3 million and $3.5 million.

Key Points:

  • Paysign's revenue in Q3 increased by 23% year-over-year to $15.3 million.
  • Adjusted EBITDA grew by 20.6% to $2.8 million.
  • Patient affordability segment increased by 219% with 66 active programs.
  • Plasma donor compensation revenue rose by 3.4% to $11.4 million.
  • Gross margins increased to 55.5%.
  • Full-year revenue is expected to be between $56.5 million and $58.5 million.
  • The company's share buyback program has $3.5 million remaining.

Outlook:

  • Paysign expects revenue growth between 20% and 24% year-over-year.
  • Gross profit margins are projected to be between 54% and 55%.
  • Operating expenses are expected to be between $30 million and $32 million.
  • The company forecasts net income between $3 million and $3.5 million for the full year.

Negative Factors:

  • Challenges in the plasma business due to external factors.
  • Ongoing legal expenses related to class action settlements are estimated at around $600,000.

Positive Factors:

  • Strong growth in the pharmaceutical segment is expected to continue through 2025.
  • The total addressable market for patient affordability services is estimated to be over $500 million.
  • Paysign’s focus on patient affordability provides a competitive advantage.

Shortcomings:

  • No patented technology, but the company possesses unique proprietary technology.

Q&A Highlights:

  • The company's strategy allows for an immediate increase in demand volume, receiving up to 15,000 requests for some programs from day one.
  • Paysign's competitive advantage is highlighted by its unique technology and transparent pricing model.

In the third quarter of 2024, Paysign, Inc. showcased strong financial performance with significant growth in the patient affordability business and steady gains in plasma donor compensation revenue. The company's strategic focus on patient affordability and its ability to efficiently incorporate new and established pharmaceutical programs have positioned it advantageously against competitors. Despite facing challenges in the plasma business and legal expenses, its optimistic outlook and proactive strategies indicate a continuous upward trajectory in financial and operational performance.

InvestingPro Forecasts: Paysign's strong financial performance in Q3 2024 is reflected in the latest InvestingPro data. The company's 27.75% revenue growth over the last twelve months aligns with the reported 23% year-over-year increase in the third quarter. This robust growth is particularly impressive considering Paysign's relatively small market capitalization of $214.94 million.

InvestingPro insights emphasize that Paysign has been highly profitable over the last twelve months, consistent with the company's positive outlook and forecasted net income for the full year. The 92.46% total return over the past year reinforces the market's favorable response to Paysign's performance and growth strategies.

However, investors should note that Paysign's stock price has significantly declined over the last three months, with a three-month total return of -17.28%. This recent drop may present an opportunity for investors who believe in the company’s long-term growth potential, especially given the expansion plans in the patient affordability segment.

The company’s P/E ratio of 27.88 and Price/Book ratio of 7.57 indicate high market expectations for future growth. This valuation is in line with Paysign's strong position in the patient affordability market and anticipated revenue growth.

For those interested in a deeper examination of Paysign’s finances and future outlook, InvestingPro offers eight additional tips that can provide valuable insights for investment decisions.